A History of Human Studies with Nerve Agents by the UK and USA

Chemical Warfare Agents: Toxicology and Treatment, Second Edition

Volumn , Issue , 2007, Pages 223-239

  Sidell, Frederick R ^a  

^a NONE

Author keywords

Diisopropyl phosphorofluoridate (DFP); Flicker threshold frequency (FTF); Human studies of nerve agents in UK and US; Liquid nerve agent toxicity on skin; Military operations and exposure to agent (MOD3)

Indexed keywords

EID: 79956118644     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470060032.ch9     Document Type: Chapter

References (101)

1. Ainsworth M and Shephard RJ (1961). The intrabronchial distribution of soluble vapours at selected rates of gas flow. In: Inhaled Particles and Vapors (CN Davies, ed.), pp. 233-247. New York, NY, USA: Pergamon Press.
2. Bertino JR, Geiger LE and Sim VM (1957). Accidental V-agent exposures. CWLR 2156.
3. Bowers MB Jr, Goodman E and Sim VR (1964). Some behavioural changes in man following anticholinesterase administration. J Nerv Ment Dis, 138, 383-389.
4. Broby BB (1954). Seventy five cases of accidental nerve gas poisoning at Dugway Proving Ground. DPG-MIB SR-5.
5. Brown EC Jr (1948). Effects of G agents on man: clinical observations. MDR 158.
6. Brown ES (1957). Distribution ofGBabsorbed by oral inhalation. CWL TM 22-1.
7. Clements JA, Moore JC, Johnson RP et al. (1952). Observations on airway resistance in men given low doses of GB by chamber exposure. MLRR 122.
8. Coombs AY and Freeman G (1954). Obsevations of the effects of GB on intellectual function in man. MLRR 310.
9. Cooper DY and Maloney JV Jr (1951). The pulmonary effects of inhalation of low concentrations of GB in man. MLRR 82.
10. Craig AB and Cornblath M (1953). Further clinical observations on workers accidentally exposed to 'G' agents. MLRR 234.
11. Craig AB and Freeman G (1953). Clinical observations on workers accidentally exposed to 'G'agents. MLRR 154.
12. Craig AB and Woodson GS (1959). Observations on the effects of exposure to nerve gas. I. Clinical observations and cholinesterase depression. Am J Med Sci, 238, 13-17.
13. Craig FN, Cummings EG, Mounter LA et al. (1967). Penetration of VX applied to the forearm at environmental temperatures of 65̊ and 115̊F. EATR 4064.
14. Craig FN, Cummings EG and Sim VM (1977). Environmental temperature and the percutaneous absorption of a cholinesterase inhibitor, VX. J Invest Dermatol, 68, 357-361.
15. Cresthull P and Oberst FW (1964). Hazard to masked men eating and drinking in a sarin-contaminated atmosphere. Armed Forces Chem J, 21-23.
16. Cresthull P, Koon WS, Musselman NP et al. (1963). Percutaneous exposure of the arm or the forearm of man to VX vapor. CRDLR 3176.
17. Cummings EG and Craig FN (1965). Effect of environmental temperature on the penetration of VX applied to the cheek. CRDLR 3256.
18. Davy E and Grosser G (1959). Some effects of certain chemical agents on motor and mental performance. CWL SP 2-20.
19. Dutreau CW, McGrath FP and Bray EH (1950). Toxicity studies on GD. 1. Median lethal concentration by inhalation in pigeons, rabbits, rats and mice. 2. Median detectable concentration by odor for man. MDRR 8.
20. Freeman G, Moore JC, Clanton BR et al. (1952). Observations on the effects of low concentrations of GB on man in rest and exercise. MLRR 148.
21. Freeman G, Marzulli FN, Craig AB et al. (1953). The toxicity of liquid GB applied to the skin of man. MLRR 217.
22. Freeman G, Marzulli F, Craig AB et al. (1954). The toxicity of liquid GA applied to the skin of man. MLRR 250.
23. Freeman G, Hilton KC and Brown ES (1956). V poisoning in man. CWLR 2025.
24. Gammill JF, Gibson JDS and Cutuly E (1954). Report of mild exposure to Gb in 21 persons. DPG-MIB SR-1.
25. Gaon MD and Werne J. Report of a study of mild exposure to GB at Rocky Mountain Arsenal. Medical Department US Army. Undated report.
26. Gazzard MF and Price-Thomas D (1975). A comparative study of central visual field changes induced by sarin vapour and physostigmine eye drops. Exp Eye Res, 20, 15-21.
27. Grob D (1956). The manifestations and treatment of poisoning due to nerve gas and other organic phosphate anticholinesterase compounds. Arch Int Med, 98, 221-239.
28. Grob D and Harvey AM (1953). The effects and treatment of nerve gas poisoning. Am J Med, 14, 52-63.
29. Grob D and Harvey JC (1958). Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate). J Clin Invest, 37, 350-368.
30. Grob D and Johns RJ (1956). Effects of V-agent organic phosphate anticholinesterase compound EA 1508 in man following accidental exposure. CWLR 2004.
31. Harvey JC (1952). Clinical observations on volunteers exposed to concentrations of GB. MLRR 114.
32. Holmes JH, Vincent T, Gingrich F et al. (1958). Final progress report. Contract Progress Report DA-18-108-M-5586.
33. Jager BV (1957). Case of GB poisoning. Contract Progress Report DA 18-108-CML-5421.
34. Johns RJ (1952). The effects of low concentrations of GB on the human eye. MLRR 100.
35. Ketchum JS, Sidell FR, Crowell EB Jr et al. (1973). Atropine, scopolamine and ditran: comparative pharmacology and antagonists in man. Psychopharmacology, 28, 121-145.
36. Kimura KK, McNamara BP and Sim VM (1960). Intravenous administration of VX in man. CRDLR 3017.
37. Koelle GB (1981). Organophosphate poisoning-an overview. Fund Appl Toxicol, 1, 129-134.
38. Koon WS, Cresthull P, Crook JW et al. (1959). Odor detection of VX vapor with and without a stabilizer. CWLR 2292.
39. Krackow EH and Fuhr I (1949). Toxicity of GA vapor by cutaneous absorption for monkey and man. MDR 179.
40. Lekov D, Dimitrov V and Mizkow Z (1966). Clinical observations of individuals contaminated by a pinacolic ester of methylfluorophosphine acid (soman). Voenno Meditsinsko Delo, 4, 47-52.
41. Lubash GD and Clark BJ (1960). Some metabolic studies in humans following percutaneous exposure to VX. CRDLR 3033.
42. Marzulli FN and Williams MR (1953). Studies on the evaporation, retention and penetration of GB applied to intact human and intact and abraded rabbit skin. MLRR 199.
43. McGrath FP, vonBerg VJ and Oberst FW (1953). Toxicity and perception of GF vapor. MLRR 185.
44. MOD1. The toxicology, symptoms, pathology and treatment of T2104 poisoning in animals. Unpublished MOD report.
45. MOD2. Eye effect of T2104. Unpublished MOD report.
46. MOD3. Tests of visual acuity affecting efficiency following exposure to a harassing dosage of tabun. Unpublished MOD report.
47. MOD4. Report on exposures of unprotected men and rabbits to low concentrations of nerve gas vapour. Unpublished MOD report.
48. MOD5. Cholinesterase as an aid to the early diagnosis of nerve gas poisoning. Part II: The variation of blood cholinesterases in man before and after the administration of very small quantities of G vapour by inhalation. Unpublished MOD report.
49. MOD6. The percutaneous toxicity of the Gcompounds. Unpublished MOD report.
50. MOD7. Psychological effects of a G-agent on men. Unpublished MOD report.
51. MOD8. Psychological effects of a G-agent on men; second report. Unpublished MOD report.
52. MOD9. Cognitive and emotional changes after exposure to GB. Unpublished MOD report.
53. MOD10. Studies of psychomotor performance. The effect of GB. Unpublished MOD report.
54. MOD11. Physical performance following inhalation of GB. Unpublished MOD report.
55. MOD12. The effects of a single exposure to GB (sarin) on human physical performance. Unpublished MOD report.
56. MOD13. The intercostal muscles and GB inhalation in man. Unpublished MOD report.
57. MOD14. The action of anticholinesterases and pressor amines on the capacity veins of the leg. Unpublished MOD report.
58. MOD15. Changes in cardiac output following the administration of sarin and other pharmacological agents. Part 3. Human experiments using the low frequency critically damped ballistocardiograph. Unpublished MOD report.
59. MOD16. GB exposure during simultaneous experimental acclimizatization to heat and cold in man. Unpublished MOD report.
60. MOD17. Detection of the 'G' gases by smell. Unpublished MOD report.
61. MOD18. An evaluation of the functional changes produced by the inhalation ofGBvapour. Unpublished MOD report.
62. MOD19. Air-way resistance changes in men exposed to GB vapour. Unpublished MOD report.
63. MOD20. The single breath administration of sarin. Unpublished MOD report.
64. MOD21. The intrabronchial distribution of soluble vapours at selected rates of gas flow. Unpublished MOD report.
65. MOD22. The retention of inhaled GB vapour. Unpublished MOD report.
66. MOD23. The effects of a minor exposure to GB on military efficiency. Unpublished MOD report.
67. MOD24. The effects of atropine and wearing respirators on the military efficiency of troops exposed to GB. Unpublished MOD report.
68. MOD25. Effect of pupil size of exposure to GB vapor. Unpublished MOD report.
69. MOD26. Estimation of the concentrations of nerve agent vapour required to produce measured degrees of miosis in rabbit and human eyes. Unpublished MOD report.
70. MOD27. The effects of a chemical agent on the eyes of aircrew. Unpublished MOD report.
71. MOD28. A comparative study of central visual field changes induced by GB (isopropylmethyl phosphonofluoridate) vapours and physostigmine salicylate eyedrops. Unpublished MOD report.
72. MOD29. Human exposure to VX vapour. Unpublished MOD report.
73. MOD30. Recovery of blood cholinesterase in man after exposure to VX. Unpublished MOD report.
74. MOD31. Passage of VX through human skin. Unpublished MOD report.
75. MOD32. Penetration of VX through clothing. Unpublished MOD report.
76. Moylan-Jones R and Price-Thomas DA (1973). Cyclopentolate in treatment of sarin miosis. Br J Pharmacol, 48, 309-313.
77. Neitlich H (1965). Effect of percutaneous GD on human studies. CRDL TM-2-21.
78. Oberst FW (1961). Factors affecting inhalation and retention of toxic vapors. In: Inhaled Particles and Vapours (CN Davies, ed.), pp. 249-265. NewYork, NY, USA: Pergamon Press.
79. Oberst FW, Koon WS and Crook JW (1952). Methods for quantitative determination ofGBabsorbed from inspired air of man during rest and exercise. MLRR 143.
80. Oberst FW, Crook JW, Christensen MK et al. (1959). Inhaled GB retention studies in man at rest and during activity. CWLR 2296.
81. Oberst FW, Koon WS, Christensen MK et al. (1968). Retention of inhaled sarin vapor and its effect on red blood cell cholinesterase activity in man. Clin Pharmacol Ther, 9, 421-427.
82. Rengstorff RH (1985). Accidental exposure to sarin; vision effects. Arch Toxicol, 56, 201-203.
83. Rubin LS and Goldberg MN (1957a). The effect of GB on dark adaption in man. III. The effect of tertiary and quaternary atropine salts on absolute scotopic threshold changes engendered by GB. CWL TR 2155.
84. Rubin LS and Goldberg MN (1957b). Effect of sarin on dark adaptation in man: threshold changes. J Appl Physiol, 11, 439-444.
85. Rubin LS and Goldberg MN (1958). Effect of tertiary and quaternary atropine salts on absolute scotopic threshold changes produced by an anticholinesterase (sarin). J Appl Physiol, 12, 305-310.
86. Rubin LS, Krop S and Goldberg MN (1957). Effect of sarin on dark adaptation in man: mechanism of action. J Appl Physiol, 11, 445-449.
87. Seed JC (1952). An accident involving vapor exposure to a nerve gas. MLRR 146.
88. Sidell FR (1967). Human responses to intravenous VX. EATR 4082.
89. Sidell FR (1974). Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol, 7, 1-17.
90. Sidell FR (1992). Clinical considerations in nerve agent intoxication. In: Chemical Warfare Agents (SM Somani, ed.), pp. 156-194. San Diego, CA, USA: Academic Press, Inc.
91. Sidell FR and Groff WA (1966). Oral toxicity of VX to humans. EATR 4009.
92. Sidell FR and GroffWA (1974). The reactivatibility of cholinesterase inhibited by VX and sarin in man. Toxicol Appl Pharmacol, 27, 241-252.
93. Sidell FR, Groff WA and Vocci F (1965). Effects of EA 3148 administered intravenously to humans. CRDL TM 2-31.
94. Sidell FR, Aghajanian GK and GroffWA (1973). The reversal of anticholinergic intoxication in man with the cholinesterase inhibitor VX. Proc Soc Exp Biol Med, 144, 725-730.
95. Sim VM (1962). Variability of different intact humanskin sites to the penetration of VX. CRDLR 3122.
96. Sim VM and Stubbs JL (1960). VX percutaneous studies in man. CRDLR 3015.
97. Sim VM, McClure C Jr, Vocci FJ et al. (1964). Tolerance of man to VX-contaminated water. CRDLR 3231.
98. Stewart WC, Madill HAD and Dyer AM (1968). Night vision in the miotic eye. Can Med Assoc J, 99, 1145-1148.
99. Vocci FJ, Hickman WE, Mehlman MA et al. (1959). The effect of n-octylamine on the penetration of VX by the percutaneous route in man. CWL TM, 24-22.
100. Ward JR (1962). Case report: exposure to a nerve gas. In: Artificial Respiration. Theory and Applications (JL Whittenberger, ed.), pp. 258-265. New York, NY, USA: Harper and Row.
101. Ward JR, Gosselin R, Comstock J et al. (1952). Case report of a severe human poisoning by GB. MLRR 151.